|
|
|
Volumn 9, Issue 11, 2011, Pages 845-852
|
|
A phase i trial of vatalanib (PTK/ZK) in combination with bevacizumab in patients with refractory and/or advanced malignancies
a
|
|
Author keywords
Bevacizumab; Phase I study; Refractory malignancy; Vatalanib
|
|
Indexed keywords
BEVACIZUMAB;
VATALANIB;
ADULT;
ADVANCED CANCER;
AGED;
ANEMIA;
ANOREXIA;
AREA UNDER THE CURVE;
ARTICLE;
ATAXIA;
BREAST CANCER;
CANCER COMBINATION CHEMOTHERAPY;
CANCER CONTROL;
CANCER GROWTH;
CHEMOTHERAPY INDUCED EMESIS;
CLINICAL ARTICLE;
COLORECTAL CANCER;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
DECREASED APPETITE;
DIARRHEA;
DIZZINESS;
DRUG BLOOD LEVEL;
DRUG CLEARANCE;
DRUG DISTRIBUTION;
DRUG DOSE ESCALATION;
DRUG DOSE REDUCTION;
DRUG ELIMINATION;
DRUG ERUPTION;
DRUG HALF LIFE;
DRUG WITHDRAWAL;
DYSPNEA;
EDEMA;
ESOPHAGUS CANCER;
EVENING DOSAGE;
FATIGUE;
FEMALE;
GASTROINTESTINAL TOXICITY;
HEART EJECTION FRACTION;
HUMAN;
HUMAN CELL;
HUMAN TISSUE;
HYPERTENSION;
KIDNEY CANCER;
LOW DRUG DOSE;
LUNG NON SMALL CELL CANCER;
MALE;
MAXIMUM PLASMA CONCENTRATION;
MAXIMUM TOLERATED DOSE;
MELANOMA;
MONOTHERAPY;
MORNING DOSAGE;
MUCOSA INFLAMMATION;
MULTIPLE CYCLE TREATMENT;
NAUSEA;
NEPHROTOXICITY;
NEUROENDOCRINE TUMOR;
NEUTROPENIA;
OVARY CANCER;
PANCREAS CANCER;
PERIPHERAL NEUROPATHY;
PHASE 1 CLINICAL TRIAL;
PROSTATE CANCER;
PROTEINURIA;
RECOMMENDED DRUG DOSE;
SARCOMA;
SIDE EFFECT;
SOLID TUMOR;
THROMBOCYTOPENIA;
THYROID CANCER;
TIME TO MAXIMUM PLASMA CONCENTRATION;
TREATMENT DURATION;
TREATMENT RESPONSE;
WEAKNESS;
WEIGHT REDUCTION;
ADULT;
AGED;
AGED, 80 AND OVER;
ANGIOGENESIS INHIBITORS;
ANTIBODIES, MONOCLONAL, HUMANIZED;
ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;
FEMALE;
HUMANS;
MALE;
MIDDLE AGED;
NEOPLASM STAGING;
NEOPLASMS;
PHTHALAZINES;
PROTEIN KINASE INHIBITORS;
PYRIDINES;
RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR;
YOUNG ADULT;
|
|
EID: 82155181647
PISSN: 15430790
EISSN: None
Source Type: Journal
DOI: None Document Type: Article |
|
Times cited : (7)
|
|
References (5)
|
